Markets
MA Stock Indexes
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
(NQ: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
Press releases about
 
< Previous 1 2 3 4 Next >
Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
August 31, 2012
from PR Newswire
Research Report on Cell Therapeutics Inc. and Advanced Cell Technology, Inc. -- Weighing the Weeks Ahead
August 29, 2012
from Marketwired News Releases
RBCC Continues Negotiations With Amarantus
August 29, 2012
from Business Wire News Releases
Favorable Legislature Introduced in 2012 Have Helped Accelerate Biotech Industry's Growth
August 15, 2012
Five Star Equities Provides Stock Research on BioSante Pharmaceuticals and Cell Therapeutics Read More
from Marketwired News Releases
RBCC: iPads, iPhones and Other Mobile Devices Inspire New Biotech Applications
August 03, 2012
from Business Wire News Releases
Cell Therapeutics, Inc. (CTI) Readies Pixuvri® European Launch and Start of Pacritinib Phase 3 Trial; Reports Second Quarter Financial Results and Milestones
August 01, 2012
- European launch of Pixuvri® targeted for Q4 2012 Read More
from PR Newswire
Cell Therapeutics Announces Institutional Investor Purchased Additional $15 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
July 31, 2012
from PR Newswire
Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
July 31, 2012
from PR Newswire
RBCC Extends Joint Venture Negotiations With Amarantus
July 25, 2012
from Business Wire News Releases
Biotech Companies -- Both Large and Small -- Showing Impressive Growth in 2012
July 17, 2012
The Paragon Report Provides Stock Research on Cell Therapeutics and Oncothyreon Read More
from Marketwired News Releases
Four Small Biotechs You Should Know: (NASDAQ: KERX), (NASDAQ: GERN), (NASDAQ: CTIC), (OTCBB: ONCS)
July 10, 2012
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO NewsWire Read More
from Marketwired News Releases
Research and Development Spending in Biotech Industry Increases for Two Consecutive Years
June 22, 2012
Five Star Equities Provides Stock Research on Aastrom Biosciences and Cell Therapeutics Read More
from Marketwired News Releases
Cell Therapeutics Readies Commercial Launch of Pixuvri® in EU; Re-Alignment of Resources and Portfolio Priorities Reduces Burn Rate by more than 30%
June 20, 2012
Pixuvri® Market Research Supports Potential Attractive Market in EU Read More
from PR Newswire
Study of Cell Therapeutics' Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
June 18, 2012
Clinical trial is being conducted by the Fred Hutchinson Cancer Research Center and the University of Washington Read More
from PR Newswire
Cell Therapeutics Appoints New Chief Medical Officer
June 14, 2012
Experienced Industry Executive, Steven E. Benner M.D., M.H.S., to Lead Cancer Drug Development Read More
from PR Newswire
Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
June 05, 2012
from PR Newswire
Cell Therapeutics Completes Acquisition of Pacritinib a Highly Selective JAK2 Inhibitor
June 04, 2012
Phase 3 Study in Patients with Myelofibrosis and Low Platelet Counts Targeted to Start in Q4-2012 Read More
from PR Newswire
Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
June 01, 2012
from PR Newswire
RBCC Anticipates Favorable Test Results of New Brain Injury Treatment
May 31, 2012
from Business Wire News Releases
Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published in The Lancet Oncology
May 31, 2012
--Lancet Oncology Editor Comments on EU Conditional Marketing Authorization Read More
from PR Newswire
Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
May 30, 2012
Proof of Concept Data to be Presented at the 9th International Symposium for Polymer Therapeutics Read More
from PR Newswire
Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
May 29, 2012
from PR Newswire
Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
May 29, 2012
from PR Newswire
RBCC: Cure for Traumatic Brain Injury May be in Sight
May 29, 2012
from Business Wire News Releases
Cell Therapeutics Announces Institutional Investor to Purchase $40 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
May 29, 2012
- Includes an initial $20 million of Series 15-1 Preferred Stock convertible into 20,000,000 shares of common stock at a conversion price of $1.00, which is a premium to the last closing bid price on... Read More
from PR Newswire
RBCC, Amarantus Move Forward with Joint Venture Discussions
May 16, 2012
from Business Wire News Releases
CTIC, KERX, OBJE and WSGI are the Stocks to Watch for May 11th from OTCPicks.com
May 11, 2012
from EmailWire.Com Press Releases
Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
May 10, 2012
-Conditional Marketing Authorization Speeds Innovative New Therapy to Patients with Unmet Medical Need Read More
from PR Newswire
Cell Therapeutics and Savient Pharmaceuticals Look to Benefit From Shift to "First to File" Patent System
May 04, 2012
The Paragon Report Provides Stock Research on Cell Therapeutics and Savient Pharmaceuticals Read More
from Marketwired News Releases
RBCC Target’s Brain Injury Treatment Awareness Campaign Reaches Milestone
May 04, 2012
from Business Wire News Releases
< Previous 1 2 3 4 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here